Sign in →

Test ID: RETZZ Multiple Endocrine Neoplasia Type 2 Syndrome, RET, Full Gene Analysis, Varies


Ordering Guidance


For a comprehensive hereditary cancer panel that includes the RET gene, consider 1 of the following:

-ENDCP / Hereditary Endocrine Cancer Panel, Varies

-HPGLP / Hereditary Paraganglioma/Pheochromocytoma Panel, Varies

-THYRP / Hereditary Thyroid Cancer Panel, Varies

 

Testing for the RET gene as part of a customized panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for this gene. For more information see FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

 

If the reason for testing indicates the MECP2 gene or Rett Syndrome, order MCP2Z / MECP2 Gene, Full Gene Analysis, Varies. If this test is ordered in this situation, it will be canceled and MCP2Z ordered and performed as the appropriate test.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Specimen Required


Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated

Additional Information: To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.


Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. Molecular Genetics: Inherited Cancer Syndromes Patient Information (T519)

3. If not ordering electronically, complete, print, and send a Oncology Test Request (T729) with the specimen.

Useful For

Evaluating patients with a personal or family history suggestive of a multiple endocrine neoplasia type 2 (MEN2) or Hirschsprung disease (HSCR)

 

Establishing a diagnosis of MEN2 or HSCR allowing for targeted cancer surveillance based on associated risks

 

Identifying variants within genes known to be associated with MEN2 or HSCR allowing for predictive testing of at-risk family members

Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in the RET gene associated with multiple endocrine neoplasia type 2 and Hirschsprung disease. See Method Description for additional details.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for multiple endocrine neoplasia type 2 and Hirschsprung disease.

Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

Reporting Name

RET Full Gene Analysis

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Clinical Information

Variants in the RET proto-oncogene are associated with two distinct and, in rare cases, overlapping clinical syndromes: multiple endocrine neoplasia type 2 (MEN2) and Hirschsprung disease (HSCR).(1)

 

MEN2:

MEN2 is an autosomal dominant cancer syndrome, which has classically been divided into 3 subtypes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC). The characteristic features of MEN2A include medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism.(1-3) MEN2B is characterized by early-onset MTC, pheochromocytoma, mucosal neuromas, and distinctive facies with enlarged lips. Other features of MEN2B include enlarged nerves of the gastrointestinal tract (ganglioneuromatosis), marfanoid habitus, hypotonia, and corneal nerve thickening.(1-3) FMTC has traditionally been diagnosed in families of MTC in the absence of pheochromocytoma or parathyroid involvement. All MEN2 subtypes are inherited in an autosomal dominant inheritance pattern. The National Comprehensive Cancer Network and the American Thyroid Association provide recommendations regarding the medical management of individuals with MEN2 syndrome.(1,4)

 

HSCR:

HSCR, also known as aganglionic megacolon, is a congenital disorder of impaired intestinal motility.(1,5,6) Variable lengths of the colon may be affected, resulting in either total aganglionosis, long-segment HSCR, or short-segment HSCR. HSCR affects approximately 1 in 5000 live births and is resolved via surgical intervention.(1,5,6) HSCR can result from chromosome abnormalities, single gene disorders (both syndromic and non-syndromic), a combination of variants in multiple genes, and unknown causes.(1,5,6) However, disease-causing RET variants are considered the most common cause of HSCR cases, particularly in families with multiple cases of HSCR and long-segment disease.(1,5,6) It has been reported that up to 50% of familial cases of HSCR and up to 33% of sporadic HSCR cases are due to RET germline variants.(1,5,6)

 

While gain-of-function variants in RET are typically associated with MEN2, loss-of-function variants have been reported in patients with HSCR including full or partial RET gene deletions.(1) In addition to clearly disease-causing RET variants that cause HSCR, additional benign variants in RET (which may not be causative in themselves) confer increased susceptibility to HSCR.(1)

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(7) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Clinical Reference

1. Eng C: Multiple endocrine neoplasia type 2. In: Adam MP, Everman DB, Mirzaa GM, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 1999. Updated August 10, 2023. Accessed April 26, 2024. Available at www.ncbi.nlm.nih.gov/books/NBK1257/

2.  Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. doi:10.1089/thy.2014.0335

3. Moline J, Eng C: Multiple endocrine neoplasia type 2: an overview. Genet Med. 2011;13(9):755-764

4. Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: Thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw. 2018;16(12):1429-1440

5. Ruiz-Ferrer M, Fernandez RM, Antinolo G, et al. A complex additive model of inheritance for Hirschsprung disease is supported by both RET mutations and predisposing RET haplotypes. Genet Med. 2006;8(11):704-710

6. de Pontual L, Pelet A, Trochet D, et al. Mutations of the RET gene in isolated and syndromic Hirschsprung's disease in human disclose major and modifier alleles at a single locus. J Med Genet. 2006;43(5):419-423

7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424

Day(s) Performed

Varies

Report Available

14 to 21 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81406

LOINC Code Information

Test ID Test Order Name Order LOINC Value
RETZZ RET Full Gene Analysis 101386-1

 

Result ID Test Result Name Result LOINC Value
614839 Test Description 62364-5
614840 Specimen 31208-2
614841 Source 31208-2
614842 Result Summary 50397-9
614843 Result 82939-0
614844 Interpretation 69047-9
614845 Resources 99622-3
614846 Additional Information 48767-8
614847 Method 85069-3
614848 Genes Analyzed 48018-6
614849 Disclaimer 62364-5
614850 Released By 18771-6
Mayo Clinic Laboratories | Genetics and Genomics Additional Information:

mcl-moltechtestmenu; mcl-hereditarycancer